Kevin Church - 24 Mar 2023 Form 4 Insider Report for Athira Pharma, Inc. (ATHA)

Role
Chief Scientific Officer
Signature
Glenna Mileson, Attorney-in-fact for Kevin Church
Issuer symbol
ATHA
Transactions as of
24 Mar 2023
Net transactions value
+$8,654
Form type
4
Filing time
27 Mar 2023, 16:57:33 UTC
Previous filing
23 Jan 2023
Next filing
16 Feb 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ATHA Common Stock Options Exercise $8,654 +6,410 +10% $1.35 68,462 24 Mar 2023 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ATHA Stock Option (Right to Buy) Options Exercise $0 -6,410 -100% $0.000000* 0 24 Mar 2023 Common Stock 6,410 $1.35 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 One-fourth of the shares subject to the option vested on January 1, 2020 and one-fourth of the shares subject to the option vest on each year thereafter.